Clinical trials: Localized Renal Cell Carcinoma
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Renal Cell Carcinoma (RCC), Cancer
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing…
- Trial name
- PROTECT (NCT01235962)
- Testing
- pazopanib
- Where
- 312 sites in United States, Argentina and 24 more
- Volunteers
- 1,538 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
VEG111485: A QTc Study of Pazopanib
This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in…
- Trial name
- NCT00861029
- Testing
- Pazopanib, Moxifloxacin
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Renal Cell, Carcinoma Colon
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Bexmarilimab treatment has demonstrated tolerable safety profile and anticancer efficacy in some subjects with advanced malignancies.
- Trial name
- RENACOL (NCT05104905)
- Testing
- bexmarilimab
- Where
- Finland
- Sponsor
- Faron Pharmaceuticals Ltd
Renal Cell Carcinoma, Kidney Cancer
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma, Kidney Cancer, Adenocarcinoma of Kidney, Adenocarcinoma, Renal
- Trial name
- NCT04260360
- Testing
- NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
- Sponsor
- NanOlogy, LLC